An enquiry to the role of CB1 receptors in neurodegeneration

Exploring Membrane Cholesterol Binding to the CB1 Receptor: A Computational Perspective

Cholesterol (CHOL) is a potential allosteric modulator of the CB1 receptor. In this work, we use atomistic molecular dynamics simulations to study how CHOL interacts with CB1 and to identify its binding sites (BS) and residence times on specific receptor zones. Our results evince minimal changes in CB1 conformational dynamics and secondary structure due to CHOL. We report five BSs, three of which coincide with previously described interaction regions (BS1, BS2, and BS3), while BS4 and BS5 are proposed as new BSs. Quantum descriptors of bonding such as Natural Bond Orbitals (NBO), Quantum Theory of Atoms in Molecules (QTAIM), and Noncovalent Interactions (NCI) analyses are employed to characterize the CHOL-BS interactions. The results show an exponential correlation between the strength of the interactions (mainly hydrogen bonds and hydrophobic contacts) and the residence time at the BSs. Although other approaches exist to identify high-affinity protein sites, our methodology integrates classical and quantum descriptions to better characterize BSs and predict ligand residence times in CB1, distinguishing persistent from transitory contacts. Since CHOL has been suggested as a potential endogenous allosteric ligand, our flexible strategy allows studying interactions that stabilize CHOL in CB1, could be extended to cannabinoid binding, and contribute to designing improved receptor ligands.

The cannabinoid receptor 1 mediates exercise-induced improvements of motor skill learning and performance in parkinsonian mouse

The endocannabinoid system (eCBs) modulates corticostriatal circuits through cannabinoid receptor 1 (CB1R). These circuits are crucial for encoding goal-directed and habitual learning behaviors and are implicated in the occurrence and progression of Parkinson's disease (PD). While exercise has been shown to enhance motor performance and reverse learning deficits in PD patients, the underlying molecular mechanisms remain unclear. We hypothesized that a treadmill training program could rescue changes in striatal plasticity and ameliorate early motor and cognitive deficits in mice subjected to an intrastriatal 6-hydroxydopamine injection. Our findings demonstrated that exercise training would improve motor performance and learning abilities in PD mice. Moreover, both immunofluorescence and reverse transcription polymerase chain reaction results suggested that corticostriatal activation decreased CB1R expression in the dorsomedial striatum of PD mice but increased expression in the substantia nigra pars reticulata following treadmill exercise. These results suggest that dysregulated CB1R expression is associated with the pathogenesis of Parkinsonism, highlighting the vital role of the CB1R in corticostriatal pathway functionality enhanced by exercise. Our results suggest the potential benefits of treadmill exercise in alleviating Parkinsonism, providing valuable insights into future potential treating strategies.

The emerging role of endocannabinoid system modulation in human fibroblast-like synoviocytes: Exploring new biomarkers and potential therapeutic targets

Human fibroblast-like synoviocytes (HFLS) are the predominant cellular component of the joint synovium. Their inflammation, known as synovitis, may contribute to the development of osteoarthritis (OA). HFLS secrete signaling factors that regulate joint function in response to mechanical trauma or OA progression. Among these factors, prostaglandin E2 (PGE2) is a key pro-inflammatory mediator, whereas prostamides, such as prostamide E2 (PME2), are synthesized from anandamide (AEA) by the same enzymes that produce PGE2. HFLS were isolated from both control subjects and OA patients (HFLS-OA) and stimulated with lipopolysaccharide (LPS, 10 ng/mL). Liquid chromatography-tandem mass spectrometry (LC-MS) was used to analyze PGE2 and PME2 secretion. Additionally, transcriptome and miRNA sequencing were conducted to identify changes in gene expression between HFLS and HFLS-OA cells. Five endocannabinoid-related genes were further validated by qPCR. Baseline PGE2 secretion differed between HFLS and HFLS-OA, with OA-related cells showing increased levels, while control cells primarily produced PME2. Upon pro-inflammatory stimulation, both cell types secreted PGE2. Changes in endocannabinoid levels and expression of endocannabinoid-related genes were observed in HFLS-OA following stimulation. miRNA sequencing revealed significant differences in miRNA expression between HFLS and HFLS-OA. Notably, HFLS-OA exhibited upregulation of Diacylglycerol lipase B (DAGLB) and downregulation of Fatty Acid-Binding Protein 4 and 5 (FABP4 and FABP5) gene expression compared to controls. The study suggests a reorganization of the endocannabinoid system in HFLS from OA patients, leading to altered cellular responses to pro-inflammatory stimuli. The molecular changes observed may drive or regulate the inflammatory response in OA synoviocytes, highlighting potential therapeutic targets. These findings provide insights into the potential mechanisms underlying OA pathogenesis and support the hypothesis of altered endocannabinoid system reactivity in HFLS in the context of inflammation.

Cognitive improvement via cortical cannabinoid receptors and choline-containing lipids

BACKGROUND AND PURPOSE

Recent research linking choline-containing lipids to degeneration of basal forebrain cholinergic neurons in neuropathological states illustrates the challenge of balancing lipid integrity with optimal acetylcholine levels, essential for memory preservation. The endocannabinoid system influences learning and memory processes regulated by cholinergic neurotransmission. Therefore, we hypothesised that activation of the endocannabinoid system may confer neuroprotection against cholinergic degeneration.

EXPERIMENTAL APPROACH

We examined the neuroprotective potential of sub-chronic treatments with the cannabinoid agonist WIN55,212-2, using ex vivo organotypic tissue cultures including nucleus basalis magnocellularis and cortex and in vivo rat models of specific cholinergic damage induced by 192IgG-saporin. Levels of lipids, choline and acetylcholine were measured with histochemical and immunofluorescence assays, along with [35S]GTPγS autoradiography of cannabinoid and muscarinic GPCRs and MALDI-mass spectrometry imaging analysis. Learning and memory were assessed by the Barnes maze and the novel object recognition test in rats and in the 3xTg-AD mouse model.

KEY RESULTS

Degeneration, induced by 192IgG-saporin, of baso-cortical cholinergic pathways resulted in memory deficits and decreased cortical levels of lysophosphatidylcholines (LPC). WIN55,212-2 restored cortical cholinergic transmission and LPC levels via activation of cannabinoid receptors. This activation altered cortical lipid homeostasis mainly by reducing sphingomyelins in lesioned animals. These modifications were crucial for memory recovery.

CONCLUSION AND IMPLICATIONS

We hypothesise that WIN55,212-2 facilitates an alternative choline source by breaking down sphingomyelins, leading to elevated cortical acetylcholine levels and LPCs. These results imply that altering choline-containing lipids via activation of cannabinoid receptors presents a promising therapeutic approach for dementia linked to cholinergic dysfunction.

Investigation in the cannabigerol derivative VCE-003.2 as a disease-modifying agent in a mouse model of experimental synucleinopathy

BACKGROUND

The cannabigerol derivative VCE-003.2, which has activity at the peroxisome proliferator-activated receptor-γ has afforded neuroprotection in experimental models of Parkinson's disease (PD) based on mitochondrial dysfunction (6-hydroxydopamine-lesioned mice) and neuroinflammation (LPS-lesioned mice). Now, we aim to explore VCE-003.2 neuroprotective properties in a PD model that also involves protein dysregulation, other key event in PD pathogenesis.

METHODS

To this end, an adeno-associated viral vector serotype 9 coding for a mutated form of the α-synuclein gene (AAV9-SynA53T) was unilaterally delivered in the substantia nigra pars compacta (SNpc) of mice. This model leads to motor impairment and progressive loss of tyrosine hydroxylase-labelled neurons in the SNpc.

RESULTS

Oral administration of VCE-003.2 at 20 mg/kg for 14 days improved the performance of mice injected with AAV9-SynA53T in various motor tests, correlating with the preservation of tyrosine hydroxylase-labelled neurons in the SNpc. VCE-003.2 also reduced reactive microgliosis and astrogliosis in the SNpc. Furthermore, we conducted a transcriptomic analysis in the striatum of mice injected with AAV9-SynA53T and treated with either VCE-003.2 or vehicle, as well as control animals. This analysis aimed to identify gene families specifically altered by the pathology and/or VCE-003.2 treatment. Our data revealed pathology-induced changes in genes related to mitochondrial function, lysosomal cell pathways, immune responses, and lipid metabolism. In contrast, VCE-003.2 treatment predominantly affected the immune response through interferon signaling.

CONCLUSION

Our study broadens the neuroprotective potential of VCE-003.2, previously described against mitochondrial dysfunction, oxidative stress, glial reactivity and neuroinflammation in PD. We now demonstrate its efficacy against another key pathogenic event in PD as α-synuclein dysregulation. Furthermore, our investigation sheds light on the molecular mechanisms underlying VCE-003.2 revealing its role in regulating interferon signaling. These findings, together with a favorable ADMET profile, enhance the preclinical interest of VCE-003.2 towards its future clinical development in PD.

Neurolipid systems: A new target for the treatment of dementia

Neurolipids comprise a diverse class of bioactive lipids that include molecules capable of activating G protein‐coupled receptors, thereby inducing systemic effects that contribute to the maintenance of homeostasis. Dementia, a non‐specific brain disorder characterized by a common set of signs and symptoms, usually arises subsequent to brain injuries or diseases and is often associated with the aging process. Individuals affected by dementia suffer from the disruption of several neurotransmitter and neuromodulatory systems, among which neurolipids play an important role, including the endocannabinoid, lysophosphatidic acid and sphingosine 1‐phosphate systems. In this review, we present an overview of the most recent and pertinent findings regarding the involvement of these neurolipidic systems in dementia, including data from a wide range of both in vitro and in vivo experiments as well as clinical trials.

Frontal Cortex Lipid Alterations During the Onset of Alzheimer's Disease

Background

Although sporadic Alzheimer's disease (AD) is a neurodegenerative disorder of unknown etiology, familial AD is associated with specific gene mutations. A commonality between these forms of AD is that both display multiple pathogenic events including cholinergic and lipid dysregulation.

Objective

We aimed to identify the relevant lipids and the activity of their related receptors in the frontal cortex and correlating them with cognition during the progression of AD.

Methods

MALDI-mass spectrometry imaging (MSI) and functional autoradiography was used to evaluate the distribution of phospholipids/sphingolipids and the activity of cannabinoid 1 (CB1), sphingosine 1-phosphate 1 (S1P1), and muscarinic M2/M4 receptors in the frontal cortex (FC) of people that come to autopsy with premortem clinical diagnosis of AD, mild cognitive impairment (MCI), and no cognitive impairment (NCI).

Results

MALDI-MSI revealed an increase in myelin-related lipids, such as diacylglycerol (DG) 36:1, DG 38:5, and phosphatidic acid (PA) 40:6 in the white matter (WM) in MCI compared to NCI, and a downregulation of WM phosphatidylinositol (PI) 38:4 and PI 38:5 levels in AD compared to NCI. Elevated levels of phosphatidylcholine (PC) 32:1, PC 34:0, and sphingomyelin 38:1 were observed in discrete lipid accumulations in the FC supragranular layers during disease progression. Muscarinic M2/M4 receptor activation in layers V-VI decreased in AD compared to MCI. CB1 receptor activity was upregulated in layers V-VI, while S1P1 was downregulated within WM in AD relative to NCI.

Conclusions

FC WM lipidomic alterations are associated with myelin dyshomeostasis in prodromal AD, suggesting WM lipid maintenance as a potential therapeutic target for dementia.

Exploring the therapeutic potential of natural compounds modulating the endocannabinoid system in various diseases and disorders: review

Cannabinoid receptors, endogenous cannabinoids (endocannabinoids), and the enzymes involved in the biosynthesis and degradation of the endocannabinoids make up the endocannabinoid system (ECS). The components of the ECS are proven to modulate a vast bulk of various physiological and pathological processes due to their abundance throughout the human body. Such discoveries have attracted the researchers' attention and emerged as a potential therapeutical target for the treatment of various diseases. In the present article, we reviewed the discoveries of natural compounds, herbs, herbs formula, and their therapeutic properties in various diseases and disorders by modulating the ECS. We also summarize the molecular mechanisms through which these compounds elicit their properties by interacting with the ECS based on the existing findings. Our study provides the insight into the use of natural compounds that modulate ECS in various diseases and disorders, which in turn may facilitate future studies exploiting natural lead compounds as novel frameworks for designing more effective and safer therapeutics.